carboplatin + irinotecan vs carboplatin + etoposide

This refers to a randomized Phase II/III clinical trial conducted by Charité University, Berlin, and the Arbeitsgemeinschaft Internistische Onkologie (AIO) Thoracic Oncology Study Group, comparing two chemotherapy combination regimens for the first-line treatment of extensive-disease small cell lung cancer (SCLC). The trial compared an experimental arm of carboplatin plus irinotecan (IP) against a control arm of carboplatin plus etoposide (EP). Carboplatin is a platinum-based alkylating agent that forms DNA crosslinks, irinotecan is a camptothecin derivative that inhibits DNA topoisomerase I, and etoposide is a podophyllotoxin derivative that inhibits DNA topoisomerase II. The study enrolled 226 patients and failed to demonstrate the superiority of the irinotecan-carboplatin combination over the standard etoposide-carboplatin regimen, with both arms showing a median progression-free survival of 6.0 months and median overall survival of 10.0 and 9.0 months, respectively.

Other names

IP vs EPcarboplatin + irinotecan vs carboplatin + etoposide-Charite University, Berlin, Germany-small cell lung cancer